Search | Clinical Trials Finder

Conditions: Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin; Drug
Lead sponsor: Cogentus Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 247
States / cities: Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more

Conditions: Ischemic Stroke
Interventions: intracranial angioplasty and stenting, intensive medical management; Device · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 30 Years to 80 Years
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 50
States / cities: Birmingham, Alabama • Phoenix, Arizona • Glendale, California + 38 more

Conditions: Cognition Disorder, Stroke, Occlusion Carotid
Interventions: Endovascular intervention, Aspirin and Clopidogrel (maximal medical Therapy); Procedure · Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Iowa City, Iowa • Durham, North Carolina

Conditions: Peripheral Arterial Disease
Interventions: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters, Balloon angioplasty; Device · Procedure
Lead sponsor: Spectranetics Corporation; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 33
States / cities: Birmingham, Alabama • Fairhope, Alabama • Little Rock, Arkansas + 28 more

Conditions: Peripheral Arterial Disease
Interventions: Not listed
Lead sponsor: Baylor Research Institute; Other
Eligibility: Not listed
Enrollment: 14,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2033
U.S. locations: 24
States / cities: Little Rock, Arkansas • Denver, Colorado • Atlanta, Georgia + 17 more

Conditions: Ischemic Foot Ulcer
Interventions: Endovascular Revascularization; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 110 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Graft Occlusion, Vascular, Coronary Restenosis, Atherosclerosis
Interventions: BO-653; Drug
Lead sponsor: Chugai Pharma USA; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 29
States / cities: Phoenix, Arizona • Tucson, Arizona • Burlingame, California + 24 more

Conditions: Chronic Limb Ischemia
Interventions: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL; Drug
Lead sponsor: Mercator MedSystems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 10
States / cities: Little Rock, Arkansas • Denver, Colorado • Saginaw, Michigan + 7 more

Conditions: Saphenous Vein Graft Atherosclerosis
Interventions: Bare Metal Stent, Drug-Eluting Stent, Blinded clopidogrel, Placebo, Thienopyridine (open-label); Device · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 25
States / cities: Tucson, Arizona • Little Rock, Arkansas • San Francisco, California + 22 more

Conditions: Coronary Atherosclerosis, Myocardial Infarction, Coronary Plaque Embolization
Interventions: Embolic Protection Device (EPD), Intracoronary Spectroscopy and Ultrasonic Evaluation, Angioplasty and Stent Implant; Device
Lead sponsor: Infraredx; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 9
States / cities: Scottsdale, Arizona • San Francisco, California • Washington D.C., District of Columbia + 6 more

Conditions: Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Heart Failure, Congestive, Heart Failure
Interventions: Beta adrenergic blockers, Platelet inhibitors, PTCA and stents, ACE Inhibitors; Drug · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 2,201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Ischemic Stroke
Interventions: MT+CAS with IV-AP, MT+CAS with PO-AP, MT+CAT with PO-AP; Procedure
Lead sponsor: Mercy Health Ohio; Other
Eligibility: 18 Years to 79 Years
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 51
States / cities: Mobile, Alabama • Glendale, California • Irvine, California + 46 more

Conditions: Peripheral Artery Disease
Interventions: Stellarex 0.035" OTW Drug-coated Angioplasty Balloon, EverCross™ 0.035 PTA Balloon Catheter; Device
Lead sponsor: Spectranetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 39
States / cities: Yuma, Arizona • Fremont, California • Los Angeles, California + 34 more

Conditions: Deep Vein Thrombosis, Venous Stasis, Venous Insufficiency, Venous Leg Ulcer, Venous Reflux, Post Thrombotic Syndrome
Interventions: Stents; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 29
States / cities: Orange, California • San Francisco, California • New Haven, Connecticut + 23 more

Conditions: Coronary Artery Disease (CAD), Chronic Total Occlusion (CTO)
Interventions: CTO Treatment Device; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Santa Clara, California

Conditions: Peripheral Vascular Disease
Interventions: Behavior, diet control, smoking cessation, exercize; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 40 Years to 85 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Superior Vena Cava Syndrome
Interventions: Superior vena cava reconstruction; Procedure
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Coronary Arteriosclerosis, Angina Pectoris
Interventions: Percutaneous coronary intervention (PCI); Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 18,876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 60
States / cities: Huntsville, Alabama • Austell, Georgia • Brunswick, Georgia + 56 more

Conditions: Peripheral Arterial Disease
Interventions: Laser Atherectomy; Device
Lead sponsor: Spectranetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Carotid Artery Disease
Interventions: RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System; Device
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2019
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Stenoses
Interventions: FLAIR Endovascular Stent Graft, PTA; Device · Procedure
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Carotid Artery Disease, Carotid Stenosis, Stroke, Atherosclerosis
Interventions: Carotid artery stenting with filter (interventional), Carotid artery endarterectomy (surgical); Device · Procedure
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 1,663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 62
States / cities: Phoenix, Arizona • Mountain View, California • Newport Beach, California + 52 more

Conditions: Coronary Artery Disease, Angina Pectoris
Interventions: Percutaneous Coronary Intervention, Coronary stent, Clopidogrel; Procedure · Device · Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Atherosclerosis, Cardiovascular Diseases, Hypertension, Renovascular, Renal Artery Obstruction
Interventions: Atacand/HCT, Caduet, GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting); Drug · Procedure
Lead sponsor: Baim Institute for Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 947 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Toledo, Ohio

Search by objective public record fields.

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis

NeuroCognition After Carotid Recanalization

Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis

Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes

Ischemic Foot Ulcers: Is Intervention Better Than Wound Care Alone

A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization

Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

Occluded Artery Trial (OAT)

Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial

ILLUMENATE Pivotal Post-Approval Study (PAS)

Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)

EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions

FIRE-PAD: Functional Improvement Through Revascularization of the Extremities for Peripheral Arterial Disease

Superior Vena Cava Reconstruction in Patients on Hemodialysis

Randomized Comparison Angioplasty Outcomes at Hospitals With and Without On-site Cardiac Surgery

An Evaluation of a Clinical Algorithm With Turbo-Power Following Treatment of Specific Morphologies

Carotid With Bivalirudin Angioplasty

Pivotal Study for the FLAIR Endovascular Stent Graft

Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)

Change in Exercise Capacity as Measured by Peak Oxygen Uptake After CTO PCI

Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions